ConductScience.org, home

Paper36979508

Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing.

Puglisi A and 7 others. Biomolecules, 2023. Cited by 8 papers, by iCite.

Cite this record

ConductScience Library. Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing. Papers, record 36979508. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36979508

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Grafting of Cyclodextrin to Theranostic Nanoparticles Improves Blood-Brain Barrier Model Crossing.
PubMed
Journal
Biomolecules
PubMed
Year
2023
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
8
iCite
Relative citation ratio, by iCite
1.14
iCite
Revised in PubMed
2024-02-14
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Puglisi AAntoninohttps://orcid.org/0000-0001-8998-0700
2Bognanni NNoemi
3Vecchio GGraziellahttps://orcid.org/0000-0001-8305-081X
4Bayir EEcehttps://orcid.org/0000-0003-4886-3860
5van Oostrum PPeter
6Shepherd DDawn
7Platt FFranceshttps://orcid.org/0000-0001-7614-0403
8Reimhult EErikhttps://orcid.org/0000-0003-1417-5576

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CyclodextrinsMajor topic
NanoparticlesMajor topic
Cricetinae
Animals
Cricetulus
Precision Medicine
Blood-Brain Barrier
Cholesterol

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
202834/Z/16/ZWellcome TrustUnited KingdomPubMed

Source PubMed

Download CSV of grants

References38

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
127999408Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases.Molecules2016https://conductscience.org/library/papers/27999408PubMed
222578502Relevance of exocytotic glutamate release from retinal glia.Neuron2012https://conductscience.org/library/papers/22578502PubMed
315573101Cyclodextrin-based pharmaceutics: past, present and future.Nat Rev Drug Discov2004https://conductscience.org/library/papers/15573101PubMed
432324281Long-term survival outcomes of patients with Niemann-Pick disease type C receiving miglustat treatment: A large retrospective observational study.J Inherit Metab Dis2020https://conductscience.org/library/papers/32324281PubMed
521629911Stabilization and functionalization of iron oxide nanoparticles for biomedical applications.Nanoscale2011https://conductscience.org/library/papers/21629911PubMed
628803710Intrathecal 2-hydroxypropyl-β-cyclodextrin decreases neurological disease progression in Niemann-Pick disease, type C1: a non-randomised, open-label, phase 1-2 trial.Lancet2017https://conductscience.org/library/papers/28803710PubMed
722484464Theranostic applications of nanoparticles in cancer.Drug Discov Today2012https://conductscience.org/library/papers/22484464PubMed
819750228Chronic cyclodextrin treatment of murine Niemann-Pick C disease ameliorates neuronal cholesterol and glycosphingolipid storage and disease progression.PLoS One2009https://conductscience.org/library/papers/19750228PubMed
926166537Noninvasive Imaging of Nanomedicines and Nanotheranostics: Principles, Progress, and Prospects.Chem Rev2015https://conductscience.org/library/papers/26166537PubMed
1019835370Ultrastable iron oxide nanoparticle colloidal suspensions using dispersants with catechol-derived anchor groups.Nano Lett2009https://conductscience.org/library/papers/19835370PubMed
119211849Niemann-Pick C1 disease gene: homology to mediators of cholesterol homeostasis.Science1997https://conductscience.org/library/papers/9211849PubMed
1234769082Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?Int J Mol Sci2021https://conductscience.org/library/papers/34769082PubMed
1320861879Revitalizing membrane rafts: new tools and insights.Nat Rev Mol Cell Biol2010https://conductscience.org/library/papers/20861879PubMed
1430216584Cyclodextrin-Based Macromolecular Systems as Cholesterol-Mopping Therapeutic Agents in Niemann-Pick Disease Type C.Macromol Rapid Commun2019https://conductscience.org/library/papers/30216584PubMed
1531131260A Novel Three-Dimensional Glioma Blood-Brain Barrier Model for High-Throughput Testing of Tumoricidal Capability.Front Oncol2019https://conductscience.org/library/papers/31131260PubMed
1634869239Cyclodextrin-Appended Superparamagnetic Iron Oxide Nanoparticles as Cholesterol-Mopping Agents.Front Chem2021https://conductscience.org/library/papers/34869239PubMed
1726027824Efficacy of 2-Hydroxypropyl-β-cyclodextrin in Niemann-Pick Disease Type C Model Mice and Its Pharmacokinetic Analysis in a Patient with the Disease.Biol Pharm Bull2015https://conductscience.org/library/papers/26027824PubMed
181537866Isolation and characterization of Chinese hamster ovary cells defective in the intracellular metabolism of low density lipoprotein-derived cholesterol.J Biol Chem1992https://conductscience.org/library/papers/1537866PubMed
1927834398Cancer nanomedicine: progress, challenges and opportunities.Nat Rev Cancer2017https://conductscience.org/library/papers/27834398PubMed
2027799764Optimizing superparamagnetic iron oxide nanoparticles as drug carriers using an in vitro blood-brain barrier model.Int J Nanomedicine2016https://conductscience.org/library/papers/27799764PubMed

See all 38 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.

PMIDTitleJournalYearIn PapersSource
41900791Cyclodextrins as Modulators of Regulated Cell Death: Implications for Immunometabolism and Therapeutic Innovation.Pharmaceutics2026https://conductscience.org/library/papers/41900791PubMed
40521219Breaking barriers: exploring blood-brain barrier crossing mechanisms with nanomedicine for effective glioma treatment.3 Biotech2025https://conductscience.org/library/papers/40521219PubMed
39707045Anti-inflammatory effects of cyclodextrin nanoparticles enable macrophage repolarization and reduce inflammation.Discov Nano2024https://conductscience.org/library/papers/39707045PubMed
38455415Galectin inhibitors and nanoparticles as a novel therapeutic strategy for glioblastoma multiforme.Am J Cancer Res2024https://conductscience.org/library/papers/38455415PubMed
37509092Cyclodextrins as Drug Release Modulators and Toxic Compound Removal Agents.Biomolecules2023https://conductscience.org/library/papers/37509092PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36979508

GET https://conductscience.org/api/papers/v1/36979508/references?page=2